Analysis Tools
immune system
|
• following induction of experimental autoimmune encephalomyelitis with MOG35-55, CD4+ T cell proliferation in draining lymph nodes is reduced compared to in similarly treated wild-type mice
• however, CD4+ T cell proliferation in the spleen is normal 9 days after MOG35-55 treatment
|
|
• in MOG35-55-treated mice
|
|
• following induction of experimental autoimmune encephalomyelitis with MOG35-55, mice exhibit increased Th17 response due to increased IL23 expression in the spleen compared with similarly treated wild-type mice
• however, in vitro differentiation of Th17 and Th1 cells is normal
|
|
• following induction of experimental autoimmune encephalomyelitis with MOG35-55, mice exhibit fewer Th1 cells per Th17 cell in the spleen and spinal cord compared with similarly treated wild-type mice
|
|
• in the central nervous system following induction of experimental autoimmune encephalomyelitis with MOG35-55
|
|
• following induction of experimental autoimmune encephalomyelitis with MOG35-55, CD4+ T cells acquire surface expression of chemokine receptors more quickly than in similarly treated mice
|
|
• levels of CCL21 and CCL19 in the lymph nodes is increased compared to in wild-type mice
|
|
• serum levels of CCR7 and CCL21 are increased compared to in wild-type mice
• 12 days post-immunization with MOG35-55, levels of CCL21 in the spinal cord are 2-fold greater than in similarly treated wild-type mice
• however, prior to immunization spinal cord levels of CCL21 are normal
|
|
• in the spleen following induction of experimental autoimmune encephalomyelitis with MOG35-55
|
|
• mice treated with MOG35-55 exhibit accelerated onset of experimental autoimmune encephalomyelitis and increased disease severity compared with similarly treated wild-type mice
• however, MOG35-55-treated mice do not exhibit increased priming in the draining lymph node and treatment with anti-CCL21 antibodies delays disease onset to wild-type
|
homeostasis/metabolism
|
• levels of CCL21 and CCL19 in the lymph nodes is increased compared to in wild-type mice
|
|
• serum levels of CCR7 and CCL21 are increased compared to in wild-type mice
• 12 days post-immunization with MOG35-55, levels of CCL21 in the spinal cord are 2-fold greater than in similarly treated wild-type mice
• however, prior to immunization spinal cord levels of CCL21 are normal
|
hematopoietic system
|
• following induction of experimental autoimmune encephalomyelitis with MOG35-55, CD4+ T cell proliferation in draining lymph nodes is reduced compared to in similarly treated wild-type mice
• however, CD4+ T cell proliferation in the spleen is normal 9 days after MOG35-55 treatment
|
|
• in MOG35-55-treated mice
|
|
• following induction of experimental autoimmune encephalomyelitis with MOG35-55, mice exhibit increased Th17 response due to increased IL23 expression in the spleen compared with similarly treated wild-type mice
• however, in vitro differentiation of Th17 and Th1 cells is normal
|
|
• following induction of experimental autoimmune encephalomyelitis with MOG35-55, mice exhibit fewer Th1 cells per Th17 cell in the spleen and spinal cord compared with similarly treated wild-type mice
|
|
• in the central nervous system following induction of experimental autoimmune encephalomyelitis with MOG35-55
|
|
• following induction of experimental autoimmune encephalomyelitis with MOG35-55, CD4+ T cells acquire surface expression of chemokine receptors more quickly than in similarly treated mice
|
cellular
|
• following induction of experimental autoimmune encephalomyelitis with MOG35-55, CD4+ T cell proliferation in draining lymph nodes is reduced compared to in similarly treated wild-type mice
• however, CD4+ T cell proliferation in the spleen is normal 9 days after MOG35-55 treatment
|
growth/size/body
|
• in MOG35-55-treated mice
|
